A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma

NCT07239986 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: BB102

Sponsor

Broadenbio Ltd., Co.